Skip to content

Transcranial alternating current stimulation (tACS) for improving motor and non-motor symptoms of Parkinson's disease (PD): a randomized, double-blind, controlled trial

Transcranial alternating current stimulation (tACS) for improving motor and non-motor symptoms of Parkinson's disease (PD): a randomized, double-blind, controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071969
Enrollment
Unknown
Registered
2023-05-30
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson‘s disease

Interventions

tACS+MIRT group:tACS+MIRT
sham-tACS+MIRT group:sham-tACS+MIRT

Sponsors

Beijing Rehabilitation Hospital, Capital Medical University, Beijing, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for primary Parkinson's disease (meet the clinical diagnostic criteria for Parkinson's disease issued by the International Society for Movement Disorders in 2015); 2. H-Y stages 1-3; 3. 45-70 years old; 4. The drug effect was stable for more than 2 weeks without adjustment and no DBS operation was performed; 5. Can walk independently without assistance (including accessories).

Exclusion criteria

Exclusion criteria: 1. The diagnosis is unclear or suspected to be Parkinson's syndrome (such as vascular, drug-induced and post-infection Parkinson's syndrome), multi-system atrophy, progressive supranuclear paralysis, etc.; 2. Cognitive, motor, speech and other disorders caused by other neurological diseases; 3. Have a history of epilepsy or other contraindications for transcranial AC stimulation; 4. Patients who are unwilling or unable to participate in MRI examination (claustrophobia); 5. Severe cognitive impairment or audio-visual impairment unable to communicate and cooperate with the examination; 6. Serious diseases such as heart, lung, liver and kidney insufficiency; 7. Can not cooperate with the completion of treatment or examination; Can't sign informed consent.

Design outcomes

Primary

MeasureTime frame
PDQ-39;

Secondary

MeasureTime frame
Motor function assessment;Evaluation of non-motor symptoms;EEG;fMRI;Biomarker;LED changes interval;

Countries

China

Contacts

Public ContactBoyan Fang

Beijing Rehabilitation Hospital,Capital Medical University, Beijing, China

fangboyanv@ccmu.edu.cn+86 188 0108 6480

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 8, 2026